Trial Profile

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients With MYC Alterations

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fimepinostat (Primary)
Indications Diffuse large B cell lymphoma
Focus Registrational; Therapeutic Use
Sponsors Curis

Most Recent Events

25 Apr 2022 Number of treatment arms increased from 1 to 3. Trial design was amended (parallel & randomized assigned).
30 Aug 2019 Status changed from active, no longer recruiting to completed.
17 Aug 2019 This trial has been completed in Germany, according to European Clinical Trials Database record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com